In recent past, mass spectrometry has further demonstrated a predominant presence of PKM2 in: RCC, bladder carcinoma, hepatocellular carcinoma, colorectal cancer, lung carcinoma, and follicular thyroid adenoma [33]. This evidence concerns the gene PKM and lung carcinoma.